880.1500 -23.10 (-2.56%)
NSE Jan 09, 2026 15:31 PM
Volume: 83,200
 

880.15
-2.56%
BOB Capital Markets Ltd.
Q2 revenue in line at Rs 6bn but EBITDA/PAT 3%/6% below our estimates due to higher opex and a product mix change
Alivus Life Sciences Ltd.'s price crossed below 50Day SMA today
More from Alivus Life Sciences Ltd.
Recommended